liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma
Linköping University, Faculty of Health Sciences. Linköping University, Department of Biomedicine and Surgery, Oncology. Östergötlands Läns Landsting, Centre of Surgery and Oncology, Department of Oncology UHL.
Show others and affiliations
2001 (English)In: Gynecologic Oncology, ISSN 0090-8258, Vol. 81, no 1, 58-62 p.Article in journal (Refereed) Published
Abstract [en]

Objective. The purpose of this phase II study was to evaluate on an intent-to-treat basis the activity and toxicity of single-agent vinorelbine (VRL) as second-line chemotherapy of patients with platinum-resistant ovarian cancer. Platinum-resistant disease was defined as disease refractory to or relapsing within 12 months after finishing platinum-containing chemotherapy. Methods. VRL (30 mg/m2) was administered intravenously as a bolus injection days 1 and 8 every 21 days. Initially, four courses of VRL were given. Patients with responding or stable disease received four more courses of VRL to a maximum of eight courses. Results. Twenty-eight of 33 eligible patients were considered evaluable for response. The overall response rate was 21% (7/33) (95% CI: 7-35). Median time to progression was 3.1 months and median survival was 10.1 months. Toxicity was generally mild. Leukopenia was the dose-limiting toxicity. CALGB grade III/IV infection was observed in 15/0% of patients. The most important nonhematologic toxicities were nausea and constipation. Grade III/IV nausea was observed in 6/0% and grade III/IV constipation in 3/3% of patients. Peripheral neurotoxicity was only a minor problem with no grade III/IV toxicity. No patients stopped treatment because of toxicity and no toxic death was reported. Conclusion. VRL was generally well tolerated, but the activity in platinum-resistant ovarian cancer was only modest, although fully comparable to other second-line treatments. Further studies are required to define the role of VRL in combination chemotherapy for ovarian cancer.

Place, publisher, year, edition, pages
2001. Vol. 81, no 1, 58-62 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-25271DOI: 10.1006/gyno.2000.6089Local ID: 9711OAI: diva2:245599
Available from: 2009-10-07 Created: 2009-10-07 Last updated: 2011-01-13

Open Access in DiVA

No full text

Other links

Publisher's full text
By organisation
Faculty of Health SciencesOncologyDepartment of Oncology UHL
In the same journal
Gynecologic Oncology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 12 hits
ReferencesLink to record
Permanent link

Direct link